Alpha Tau Medical (NASDAQ:DRTS – Get Free Report) posted its quarterly earnings results on Thursday. The company reported ($0.33) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.15) by ($0.18), reports.
Alpha Tau Medical Stock Performance
DRTS stock traded down $0.68 during mid-day trading on Thursday, reaching $11.33. The company had a trading volume of 1,239,684 shares, compared to its average volume of 589,480. The company has a quick ratio of 7.79, a current ratio of 11.09 and a debt-to-equity ratio of 0.15. The stock has a market capitalization of $1.02 billion, a P/E ratio of -10.90 and a beta of 1.28. Alpha Tau Medical has a one year low of $3.43 and a one year high of $15.79. The stock’s 50-day simple moving average is $13.90 and its two-hundred day simple moving average is $10.99.
Insider Activity at Alpha Tau Medical
In other news, CFO Raphi Levy sold 2,871 shares of the company’s stock in a transaction dated Friday, August 21st. The shares were sold at an average price of $15.00, for a total transaction of $43,065.00. Following the completion of the transaction, the chief financial officer owned 90,180 shares in the company, valued at approximately $1,352,700. This represents a 3.09% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 39.50% of the company’s stock.
Wall Street Analysts Forecast Growth
A number of analysts have weighed in on DRTS shares. Barclays increased their target price on shares of Alpha Tau Medical from $17.00 to $30.00 and gave the stock an “overweight” rating in a report on Thursday, September 3rd. Benchmark reaffirmed a “buy” rating on shares of Alpha Tau Medical in a research report on Thursday, July 23rd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Alpha Tau Medical in a research report on Thursday, October 15th. Piper Sandler upgraded shares of Alpha Tau Medical from a “neutral” rating to an “overweight” rating and increased their price objective for the stock from $8.00 to $22.00 in a research note on Wednesday, November 11th. Finally, UBS Group reissued a “buy” rating on shares of Alpha Tau Medical in a report on Tuesday. Seven research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $18.20.
View Our Latest Analysis on Alpha Tau Medical
About Alpha Tau Medical
Alpha Tau Medical Ltd. is an Israel-based medical technology company developing Alpha DaRT, an investigational radiation treatment for solid tumors. The company was founded in 2016 and is headquartered in Jerusalem. Alpha DaRT uses tiny sources containing radium-224 that are placed directly inside a tumor. As the material decays, it releases alpha-emitting atoms that travel a short distance through the tumor, aiming to destroy cancer cells while limiting exposure to nearby healthy tissue. The company is conducting clinical development of Alpha DaRT for multiple types of solid tumors, with research and clinical trials in Israel and other countries, including the United States and Japan.
Recommended Stories
- Five stocks we like better than Alpha Tau Medical
- Grand Theft Auto VI Arrives: Why Take-Two Is a Waiting Game
- Greg Abel Makes His Next Moves: Inside Berkshire’s Q3 Portfolio
- Walmart Earnings Change the Narrative as Digital Growth Lifts Outlook
- Whatever Happens to Copper Next, These 3 Investments Offer Different Ways to Play It
Receive News & Ratings for Alpha Tau Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alpha Tau Medical and related companies with MarketBeat.com's FREE daily email newsletter.
